Neos Therapeutics Inc (NASDAQ:NEOS) shares dropped 7.7% on Monday . The company traded as low as $2.01 and last traded at $2.05. Approximately 509,073 shares were traded during trading, an increase of 37% from the average daily volume of 371,612 shares. The stock had previously closed at $2.22.
NEOS has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, December 26th. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Wednesday, January 16th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $9.69.
The company has a quick ratio of 1.37, a current ratio of 1.55 and a debt-to-equity ratio of 5.51. The stock has a market cap of $105.39 million, a PE ratio of -1.31 and a beta of 0.99.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The company had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $18.90 million. Analysts forecast that Neos Therapeutics Inc will post -0.66 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Nantahala Capital Management LLC purchased a new position in Neos Therapeutics during the fourth quarter worth about $7,400,000. Stonepine Capital Management LLC lifted its position in Neos Therapeutics by 1,747.2% during the fourth quarter. Stonepine Capital Management LLC now owns 4,210,153 shares of the company’s stock worth $6,947,000 after buying an additional 3,982,234 shares during the period. Broadfin Capital LLC purchased a new position in Neos Therapeutics during the fourth quarter worth about $4,321,000. Sphera Funds Management LTD. lifted its position in Neos Therapeutics by 164.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,201,697 shares of the company’s stock worth $3,633,000 after buying an additional 1,370,000 shares during the period. Finally, BlackRock Inc. lifted its position in Neos Therapeutics by 28.8% during the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after buying an additional 610,660 shares during the period. Institutional investors and hedge funds own 50.83% of the company’s stock.
Neos Therapeutics Company Profile (NASDAQ:NEOS)
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Recommended Story: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.